{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?nctId=NCT05516498",
    "query": {
      "nctId": "NCT05516498"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 1,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-15T20:07:40.190Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05516498",
      "title": "Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)",
          "type": "DRUG"
        },
        {
          "name": "Part A: zibotentan (dose B) + dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet)",
          "type": "DRUG"
        },
        {
          "name": "Part B: placebo (matching zibotentan capsule) + dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Part B: zibotentan (dose A) + dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Part B: zibotentan (dose B) + dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Part B: zibotentan (dose C) + dapagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 205,
      "start_date": "2022-10-31",
      "completion_date": "2025-07-17",
      "has_results": false,
      "last_update_posted_date": "2025-08-15",
      "last_synced_at": "2026-09-15T20:07:40.190Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Pasadena, California • San Francisco, California + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "West Hollywood",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05516498"
    }
  ]
}